Candriam S.C.A. Bio N Tech Se Transaction History
Candriam S.C.A.
- $16.8 Billion
- Q2 2025
A detailed history of Candriam S.C.A. transactions in Bio N Tech Se stock. As of the latest transaction made, Candriam S.C.A. holds 586,736 shares of BNTX stock, worth $62.2 Million. This represents 0.37% of its overall portfolio holdings.
Number of Shares
586,736
Previous 670,955
12.55%
Holding current value
$62.2 Million
Previous $61.1 Million
2.25%
% of portfolio
0.37%
Previous 0.39%
Shares
19 transactions
Others Institutions Holding BNTX
# of Institutions
317Shares Held
40.8MCall Options Held
1.37MPut Options Held
1.52M-
Baillie Gifford & CO8.04MShares$853 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$449 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$424 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$382 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$201 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.7B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...